The Future of  Skin Cancer Detection

Meet DermaSensor: a non-invasive, AI-powered device that provides an immediate, objective result for skin cancer risk.

Exclusive offer: 50% off your first 3 months*

96% sensitivity for detecting all three  common skin cancers ¹

Proprietary, FDA-cleared algorithm provides  instant results

First FDA device cleared for primary care use

“With integrating DermaSensor’s innovative technology into our practice, we can now offer enhanced skin cancer assessment capabilities right in our community, ensuring timely referrals for our patients.”

As Featured In

Bridging the Gap in Skin Cancer Detection: Innovative Solutions for Rapid Diagnosis

Skin cancer is a pervasive and underdiagnosed health concern in the United States, exacerbated by the inefficiencies within the healthcare system. Primary care physicians, who are on the frontline to appropriately treat and triage a host of conditions, have had a lack of adequate diagnostic aids to assess skin lesions. There is an unmet need for tools to improve identification of lesions requiring referral, which may otherwise lead to delayed or missed detection of skin cancer.

Key Features

96% sensitivity for detection across all three common skin cancers¹

Proprietary algorithm yields instant assessment.

Ergonomically designed, wireless, and easy to grip.

Always on, ensuring readiness when needed.

How it Works?

Identify lesions suggestive of skin cancer on the patient

Apply handheld DermaSensor device to the lesion and initiate first recording

Five spectral recordings are taken from the skin lesion to complete one scan

DermaSensor's algorithm analyzes spectral data and delivers assessment in seconds

Technology

DermaSensor’s tip reflects and records quick bursts of light off the lesion’s cellular and sub-cellular content.

The light is analyzed by the built-in computer to provide information to help physicians assess skin lesions (including melanomas, squamous cell carcinomas, and basal cell carcinomas) to aid in a referral decision.

By examining the difference in light scattering, DermaSensor determines if the skin lesion output is “Monitor” or “Investigate Further,” with the latter result including a 1-10 confidence score for malignancy likelihood.

Elastic Scattering Spectroscopy (ESS) has been validated in 30+ publications on clinical studies for various cancer types. Many studies have shown ESS to provide information that is comparable to histopathologic assessment in the analysis of cellular microscopic structure.

“As a dermatologist that trained PCPs at One Medical for years, I think this device will be transformational for PCPs correctly managing suspicious lesions.”

Secure Your Introductory Pricing Today!

$199/month(Up to 5 patients)

$399/month(Unlimited Users & Scans)

Discover what other practitioners are saying.

Our study indicates that DermaSensor’s ESS device has the potential to enhance the detection of skin malignancies in the primary care setting. This technology not only improved PCPs’ sensitivity for lesion referral but also significantly increased their confidence, both of which are particularly important for non-specialists

Laura Korb Ferris, MD

Professor Of Dermatology And Director Of The University Of Pittsburgh Department Of Dermatology Clinical Trials Unit

This is a rare quadruple win in medicine! It’s a win for the patients, a win for the providers, a win for dermatologists, and a win for insurers. For the patients, it may provide peace of mind with an adjunctive medical device for detecting all three common skin cancers. For the providers, DermaSensor generates an immediate, objective assessment of suspicious skin lesions for timely referrals. For dermatologists, DermaSensor helps prioritize patients requiring a higher level of care and more immediate attention. And for the insurers, this can result in prompt evaluation and treatment if malignancy is detected.

Dr. Kevin Wong, MD

Founder of PT Family Medicine. Past President of the Pennsylvania Academy of Family Physicians

As skin cancer rates continue to rise, the need for accurate and efficient skin cancer detection in primary care is increasingly important. These studies have shown the ESS device benefits physicians, and it is also a non-invasive, easy-to-use solution for instantaneously evaluating suspicious lesions.

Daniel Siegel, MD

Clinical Professor of Dermatology at SUNY Downstate and former President of AAD. Principal Investigator for DermaSensor's FDA Pivotal Clinical Utility Study

© 2024 DermaSensor, Inc. All Rights Reserved.
*Applies to $399 monthly subscription rate only (unlimited users and patients).
Please read the Legal Notice for further details.
View device indications for use, warnings, and precautions (no known contraindications).
Clinical Evidence Available Upon Request

80.0009.4

The Future of Skin Cancer Detection